Cataract Therapeutics

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

Abbreviated New Drug Applications seek potential approval of a generic drug product.

Physicians should consider the roles of verbal and ocular anesthesia.

The angled bow-tie pattern of astigmatism was corrected more accurately compared with the asymmetric bow-tie pattern of astigmatism

A singular celebration of science over the decades

Despite recognition of lenticular glutathione’s importance in lens formation for decades, why it declines with age remains a mystery.

Alice Epitropoulos, MD, discusses the importance of considering ocular surface health in cataract surgery patients.

An expert discusses how to ensure optimal administration.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.

Surgeon notes there is no good solution for ending use of topical medications

Ophthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.

The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.

The procedure ensures the removal of cortical remnants, capsular fibrosis during cataract surgery.

Using a cloud-based digital health option can save time during surgery.

OCS-01 is being reviewed for the treatment of inflammation and pain after cataract surgery, with the potential to become the first once-daily, topical and preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

An investigator at Anglia Ruskin University is leading work on an anti-cataract drug, which has had positive results in lab tests.

Formosa Pharmaceuticals, AimMax Therapeutics unveiled data from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate (0.05%).

Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

Proper measurement of the eye is key to predicting lens strength.

The study reviews the outcomes following penetrating, closed trauma–related injuries.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging